Current hepatocellular carcinoma systemic pharmacological treatment options

Liver cancer is the sixth common cancer and the second leading cause of cancer death worldwide. Hepatocellular carcinoma (HCC) accounts for ~90% of cases of liver cancer and is the fourth most common cause of cancer-related death in the world. Up to now, 4 oral multityrosine kinase inhibitors (soraf...

Full description

Saved in:
Bibliographic Details
Published in:World cancer research journal 2023-01, Vol.10
Main Authors: A. Caturano, M. Monda, R. Galiero, E. Vetrano, C. Giorgione, A. Mormone, M. Rinaldi, R. Marfella, F. Sasso, L. Rinaldi
Format: Article
Language:English
Subjects:
atezolizumab plus bevacizumab
cabozantinib
hepatocellular carcinoma
ipilimumab plus nivolumab
lenvatinib
nivolumab
pembrolizumab
ramucirumab
regorafenib
sorafenib
systemic pharmacological treatment
tremelimumab plus durvalumab
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Liver cancer is the sixth common cancer and the second leading cause of cancer death worldwide. Hepatocellular carcinoma (HCC) accounts for ~90% of cases of liver cancer and is the fourth most common cause of cancer-related death in the world. Up to now, 4 oral multityrosine kinase inhibitors (sorafenib, lenvatinib, regorafenib and cabozantinib), 1 anti-angiogenic antibody (ramucirumab) and 5 immune checkpoint inhibitors, alone or in combination (atezolizumab in combination with bevacizumab, ipilimumab in combination with nivolumab, tremelimumab in combination with durvalumab, nivolumab and pembrolizumab in monotherapy) have been commercialized for advanced HCC patients’ treatment. The aim of this editorial is to provide an insight in current hepatocellular carcinoma systemic pharmacological treatment options.
ISSN:2372-3416
DOI:10.32113/wcrj_20235_2570